Older adults have a lower risk of any severity of bleeding (includes both major and minor bleeding) when treated with aspirin or clopidogrel compared to warfarin. However, if minor bleeding is excluded, only the subgroup of patients aged 80 years or older demonstrate a lower risk the of major bleeding with antiplatelet agents.
Results

Commentary
Several systematic reviews have previously shown that the risk of bleeding with long-term treatment with aspirin was lower than with warfarin. 2, 3 It is common clinical practice to use antiplatelet agents as alternatives to anticoagulation in patients with atrial fibrillation and low risk of stroke or for those with contraindications to anticoagulants. However, the latest guidelines no longer recommend the use of aspirin for atrial fibrillation regardless of age. 4 Although it is well known that age increases the risk of bleeding, this systematic review aimed to evaluate whether bleeding risk is equivalent among all antithrombotic drugs.
This meta-analysis of 43,199 patients revealed that the risk of major hemorrhage in older adults is similar for antiplatelet agents and warfarin. Bleeding of any severity was less frequent with aspirin or clopidogrel than with warfarin (risk ratio 0.46; 95% confidence interval [CI] 0.30 to 0.73); this difference was primarily driven by more common minor bleeding events in the warfarin group. Earlier randomized controlled trials comparing aspirin and warfarin targeted a higher international normalized ratio (2 to 4.5) and subsequently had significantly higher risks of major bleeding with warfarin. 5 More recent randomized controlled trials, targeting international normalized ratios of 2 to 3, showed no difference in the risk of major hemorrhage in older patients. 6, 7 The data from this systematic review do not support the widespread notion that antiplatelet agents have a lower risk of major bleeding in comparison with anticoagulants. The belief that antiplatelet agents are safer than anticoagulants disagrees mechanistically with the early steps in hemostasis, involving platelet activation and aggregation. Vascular injury results in platelet activation and the simultaneous release of endothelial tissue factor, subsequently initiating the coagulation cascade. Once the platelet plug is formed during primary hemostasis, the clotting cascade forms fibrin to stabilize the plug, suggesting the equal importance of platelets and coagulation factors in preventing extravascular extravasation of blood.
In 2010, a study 8 examining more than 118,000 Danish patients with atrial fibrillation found that major bleeding events (ie, gastrointestinal, intracranial, urinary tract, and airway) requiring hospital admission or causing death were comparable. With warfarin as a reference, the hazard ratio for nonfatal bleeding from aspirin alone was 0.84 (95% CI 0.80 to 0.89) and from clopidogrel alone was 0.94 (95% CI 0.76 to 1.16). Additionally, in comparison with warfarin, the hazard ratio for fatal bleeding from aspirin alone was 1.37 (95% CI 1.13 to 1.65) and from clopidogrel alone was 2.22 (95% CI 1.30 to 3.77), suggesting an increase in the risk of fatal bleeding with antiplatelet agents in comparison with warfarin for bleeding events.
The majority of emergency medicine literature is focused on anticoagulant-and antiplateletassociated bleeding in trauma patients; more research is needed to determine the risk of all-cause bleeding in patients receiving antiplatelet and anticoagulant drugs. Because of reduced effectiveness, the 2014 American Heart Association, American College of Cardiology, and Heart Rhythm Society guidelines 4 state that aspirin should not be used as an alternative to warfarin for patients with atrial fibrillation. For patients with nonvalvular atrial fibrillation and a CHA 2 DS 2 -VASc score of 1, aspirin "may be considered" as an alternative to oral anticoagulant therapy or no antithrombotic therapy. 4 In conclusion, antiplatelet agents are associated with the same risk of major bleeding events as anticoagulants, and clinical evaluation for potential bleeding complications should be commensurate with this equivalent risk. 
DATA EXTRACTION AND SYNTHESIS
Two authors independently assessed every study for inclusion, assessed its risk of bias, and extracted data with predefined forms. The main outcome analyzed was major bleeding, defined as clinically overt bleeding involving a critical anatomic site or associated with death, permanent disability, a decrease in hemoglobin concentration greater than 2 g/dL, or a patient's requiring transfusion of greater than or equal to 2 units of whole blood or packed RBCs. Secondary outcomes were intracranial bleeding, any severity of bleeding, and all-cause mortality. Outcomes were analyzed at 12 months. The risk of bias was assessed with the tool developed by the Cochrane Collaboration. 1 Subgroup analyses were predefined by age (patients 65 to 79 years, or 80 years or older), by indication for anticoagulation (atrial fibrillation or other indications), and by aspirin dose (less than or greater than 100 mg/day).
